GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.77 EUR
+0.12 (+4.53%)
Taking everything into account, ALGEN scores 5 out of 10 in our fundamental rating. ALGEN was compared to 81 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALGEN get a neutral evaluation. Nothing too spectacular is happening here. ALGEN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
ALGEN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
ALGEN has a better Return On Assets (3.96%) than 76.54% of its industry peers.
ALGEN's Return On Equity of 7.06% is fine compared to the rest of the industry. ALGEN outperforms 76.54% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.13%, ALGEN belongs to the top of the industry, outperforming 80.25% of the companies in the same industry.
ALGEN had an Average Return On Invested Capital over the past 3 years of 5.56%. This is significantly below the industry average of 11.80%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
ALGEN has a Profit Margin of 5.86%. This is in the better half of the industry: ALGEN outperforms 79.01% of its industry peers.
With a decent Operating Margin value of 8.09%, ALGEN is doing good in the industry, outperforming 75.31% of the companies in the same industry.
ALGEN has a better Gross Margin (92.34%) than 87.65% of its industry peers.
ALGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
ALGEN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
The debt/assets ratio for ALGEN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.37 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALGEN's Altman-Z score of 2.37 is fine compared to the rest of the industry. ALGEN outperforms 67.90% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN's Debt to FCF ratio of 1.41 is amongst the best of the industry. ALGEN outperforms 85.19% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ALGEN is not too dependend on debt financing.
The Debt to Equity ratio of ALGEN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.37 |
ROIC/WACC0.87
WACC7.07%
2.3 Liquidity
ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Current ratio of 1.92. This is comparable to the rest of the industry: ALGEN outperforms 41.98% of its industry peers.
A Quick Ratio of 1.81 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN's Quick ratio of 1.81 is in line compared to the rest of the industry. ALGEN outperforms 44.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
ALGEN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.04%.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.19, the valuation of ALGEN can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 90.12% of the companies listed in the same industry.
ALGEN is valuated cheaply when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.19 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaper than 91.36% of the companies in the same industry.
95.06% of the companies in the same industry are more expensive than ALGEN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.8 | ||
| EV/EBITDA | 4.59 |
4.3 Compensation for Growth
ALGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALGEN (12/30/2025, 7:00:00 PM)
2.77
+0.12 (+4.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners10.39%
Ins Owner ChangeN/A
Market Cap26.26M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Analysts86.67
Price Target6.02 (117.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.19 | ||
| Fwd PE | N/A | ||
| P/S | 1.23 | ||
| P/FCF | 5.8 | ||
| P/OCF | 3.8 | ||
| P/B | 1.48 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | 4.59 |
EPS(TTM)0.21
EY7.58%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY17.26%
OCF(TTM)0.73
OCFY26.31%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.37 |
F-Score5
WACC7.07%
ROIC/WACC0.87
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.
Can you provide the valuation status for GENOWAY SA?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
How profitable is GENOWAY SA (ALGEN.PA) stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.
How financially healthy is GENOWAY SA?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.